Information Barriers to the Implementation of Economic Evaluations in Japan
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 20 (Supplement) , 9-15
- https://doi.org/10.2165/00019053-200220002-00002
Abstract
With increasing cost-containment pressures within healthcare systems worldwide, economic evaluations of medical technologies, particularly pharmaceuticals, are used to aid the allocation of expenditure and resources. Facing similar pressures, Japan will probably also introduce economic evaluation of health technology. However, the structure of the healthcare system in Japan does not lend itself naturally to the collection of the epidemiological and cost data required for economic evaluations in medicine. In addition, there are no formal methodological guidelines in place for these analyses. To overcome these information barriers in Japan, progress may be aided by the adoption of approaches used in other countries for data collection and guideline development.Keywords
This publication has 7 references indexed in Scilit:
- Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries?PharmacoEconomics, 2002
- The Revised Canadian Guidelines for the Economic Evaluation of PharmaceuticalsPharmacoEconomics, 1999
- Canada's new guidelines for the economic evaluation of pharmaceuticals.1996
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996
- The Canadian “Model” for the Establishment of GuidelinesDrug Information Journal, 1996
- A Comparative Review of Pharmacoeconomic GuidelinesPharmacoEconomics, 1995
- Economic Evaluation of Neonatal Intensive Care of Very-Low-Birth-Weight InfantsNew England Journal of Medicine, 1983